Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREAKFAST trial
2023-508920-37-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of metformin delayed release and metformin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Pathologic complete response. Planned start Nov 2023; status: authorised.
02
Drugs
metformin delayed releasemetformin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-508920-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508920-37-00.